Literature DB >> 23775505

Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia.

Jörn Lötsch1, Carsten Skarke, Jutta Darimont, Michael Zimmermann, Lutz Bräutigam, Gerd Geisslinger, Alfred Ultsch, Bruno G Oertel.   

Abstract

Surrogates may provide easy and quick access to information about pharmacological parameters of interest that can be directly measured only with difficulty. Surrogates have been proposed for opioid blood concentrations to replace invasive sampling, serving as a basis for target-controlled infusion systems to optimize analgesia. We aimed at identifying surrogates of remifentanil steady-state blood concentrations with relevance for its clinical, in particular, analgesic, effects. A "single ascending dose" study design assessed concentration-dependent effects of remifentanil in a double-blind randomized fashion in 16 healthy volunteers. Remifentanil was administered by means of computerized infusion aimed at steady-state effect-site concentrations of 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml (one concentration per subject, two subjects per concentration). Arterial remifentanil blood concentrations were measured during apparent steady state. Pharmacodynamic parameters were measured at baseline and during steady-state conditions. Potential surrogate parameters included the pupil diameter, the amplitude of pupil light reflex, and the performance in a visual tracking task. Clinical parameters were analgesia to experimental pain, nausea, tiredness, and visual acuity. Remifentanil blood concentrations were well predicted by its effects on the pupil light reflex amplitude, better than by its miotic effects. However, the best prediction for both remifentanil blood concentrations and analgesic effects was obtained using a combination of three surrogate parameters (pupil diameter, light reflex amplitude, and tracking performance). This combination of pharmacodynamic parameters provided even better predictions of analgesia than could be obtained using the measured opioid blood concentrations. Developing surrogates only for opioid blood concentrations is insufficient when opioid effects are the final goal. Combining pharmacodynamic surrogate parameters seems to provide a promising approach to obtain acceptable predictions of relevant clinical effects, with better results than obtained with measuring or estimating blood concentrations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23775505     DOI: 10.1007/s00210-013-0889-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  50 in total

1.  Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences.

Authors:  Igor Mitrovic; Marta Margeta-Mitrovic; Semon Bader; Markus Stoffel; Lily Y Jan; Allan I Basbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-20       Impact factor: 11.205

Review 2.  Administration and monitoring of intravenous anesthetics.

Authors:  Marko M Sahinovic; Anthony R Absalom; Michel M R F Struys
Journal:  Curr Opin Anaesthesiol       Date:  2010-12       Impact factor: 2.706

3.  The importance of assessing the fit of logistic regression models: a case study.

Authors:  D W Hosmer; S Taber; S Lemeshow
Journal:  Am J Public Health       Date:  1991-12       Impact factor: 9.308

4.  Genetic-epigenetic interaction modulates μ-opioid receptor regulation.

Authors:  Bruno G Oertel; Alexandra Doehring; Bianca Roskam; Mattias Kettner; Nadja Hackmann; Nerea Ferreirós; Peter H Schmidt; Jörn Lötsch
Journal:  Hum Mol Genet       Date:  2012-08-08       Impact factor: 6.150

5.  Necessity and risks of arterial blood sampling in healthy volunteer studies.

Authors:  Bruno Georg Oertel; Johannes Vermehren; Michael Zimmermann; Thomas Tao Huynh; Alexandra Doehring; Nerea Ferreiros; Stephan Senzel; Thomas Schmitz-Rixen; Matthias Erbe; Gerd Geisslinger; Sebastian Harder; Martin S Angst; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 6.447

6.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Authors:  C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

7.  EEG-controlled closed-loop dosing of propofol in rats.

Authors:  A Tzabazis; H Ihmsen; M Schywalsky; H Schwilden
Journal:  Br J Anaesth       Date:  2004-02-20       Impact factor: 9.166

8.  Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum.

Authors:  L J Sim; D E Selley; R Xiao; S R Childers
Journal:  Eur J Pharmacol       Date:  1996-06-20       Impact factor: 4.432

9.  A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline.

Authors:  T Hummel; C Hummel; I Friedel; E Pauli; G Kobal
Journal:  Br J Clin Pharmacol       Date:  1994-04       Impact factor: 4.335

10.  Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers.

Authors:  T D Egan; C F Minto; D J Hermann; J Barr; K T Muir; S L Shafer
Journal:  Anesthesiology       Date:  1996-04       Impact factor: 7.892

View more
  1 in total

Review 1.  Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.

Authors:  Carmen Walter; Claudia Knothe; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2016-07       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.